These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

896 related articles for article (PubMed ID: 32579807)

  • 1. Triple Inhaled Therapy at Two Glucocorticoid Doses in Moderate-to-Very-Severe COPD.
    Rabe KF; Martinez FJ; Ferguson GT; Wang C; Singh D; Wedzicha JA; Trivedi R; St Rose E; Ballal S; McLaren J; Darken P; Aurivillius M; Reisner C; Dorinsky P;
    N Engl J Med; 2020 Jul; 383(1):35-48. PubMed ID: 32579807
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of Budesonide/Glycopyrronium/Formoterol Fumarate Metered Dose Inhaler (BGF MDI) Versus Other Inhaled Corticosteroid/Long-Acting Muscarinic Antagonist/Long-Acting β
    Ferguson GT; Darken P; Ballal S; Siddiqui MK; Singh B; Attri S; Holmgren U; de Nigris E
    Adv Ther; 2020 Jun; 37(6):2956-2975. PubMed ID: 32335859
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase III study of triple therapy with budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler 320/18/9.6 μg and 160/18/9.6 μg using co-suspension delivery technology in moderate-to-very severe COPD: The ETHOS study protocol.
    Rabe KF; Martinez FJ; Ferguson GT; Wang C; Singh D; Wedzicha JA; Trivedi R; St Rose E; Ballal S; McLaren J; Darken P; Reisner C; Dorinsky P
    Respir Med; 2019; 158():59-66. PubMed ID: 31605923
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Functional respiratory imaging assessment of budesonide/glycopyrrolate/formoterol fumarate and glycopyrrolate/formoterol fumarate metered dose inhalers in patients with COPD: the value of inhaled corticosteroids.
    van den Berge M; De Backer J; Van Holsbeke C; De Backer W; Trivedi R; Jenkins M; Dorinsky P; Aurivillius M
    Respir Res; 2021 Jul; 22(1):191. PubMed ID: 34210340
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of single-inhaler extrafine triple therapy versus inhaled corticosteroid plus long-acting beta2 agonist in eastern Asian patients with COPD: the TRIVERSYTI randomised controlled trial.
    Zheng J; Baldi S; Zhao L; Li H; Lee KH; Singh D; Papi A; Grapin F; Guasconi A; Georges G
    Respir Res; 2021 Mar; 22(1):90. PubMed ID: 33757520
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Triple therapy with budesonide/glycopyrrolate/formoterol fumarate with co-suspension delivery technology versus dual therapies in chronic obstructive pulmonary disease (KRONOS): a double-blind, parallel-group, multicentre, phase 3 randomised controlled trial.
    Ferguson GT; Rabe KF; Martinez FJ; Fabbri LM; Wang C; Ichinose M; Bourne E; Ballal S; Darken P; DeAngelis K; Aurivillius M; Dorinsky P; Reisner C
    Lancet Respir Med; 2018 Oct; 6(10):747-758. PubMed ID: 30232048
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): a double-blind, parallel group, randomised controlled trial.
    Papi A; Vestbo J; Fabbri L; Corradi M; Prunier H; Cohuet G; Guasconi A; Montagna I; Vezzoli S; Petruzzelli S; Scuri M; Roche N; Singh D
    Lancet; 2018 Mar; 391(10125):1076-1084. PubMed ID: 29429593
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Systematic review and network meta-analysis of the efficacy and safety of glycopyrrolate/formoterol fumarate metered dose inhaler in comparison with other long-acting muscarinic antagonist/long-acting β
    Siddiqui MK; Shukla P; Jenkins M; Ouwens M; Guranlioglu D; Darken P; Biswas M
    Ther Adv Respir Dis; 2019; 13():1753466619894502. PubMed ID: 31868101
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Benefits of budesonide/glycopyrronium/formoterol fumarate dihydrate on lung function and exacerbations of COPD: a post-hoc analysis of the KRONOS study by blood eosinophil level and exacerbation history.
    Muro S; Kawayama T; Sugiura H; Seki M; Duncan EA; Bowen K; Marshall J; Megally A; Patel M
    Respir Res; 2024 Aug; 25(1):297. PubMed ID: 39103901
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reduced All-Cause Mortality in the ETHOS Trial of Budesonide/Glycopyrrolate/Formoterol for Chronic Obstructive Pulmonary Disease. A Randomized, Double-Blind, Multicenter, Parallel-Group Study.
    Martinez FJ; Rabe KF; Ferguson GT; Wedzicha JA; Singh D; Wang C; Rossman K; St Rose E; Trivedi R; Ballal S; Darken P; Aurivillius M; Reisner C; Dorinsky P
    Am J Respir Crit Care Med; 2021 Mar; 203(5):553-564. PubMed ID: 33252985
    [No Abstract]   [Full Text] [Related]  

  • 11. Long-Term Safety and Efficacy of Budesonide/Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler Formulated Using Co-Suspension Delivery Technology in Japanese Patients with COPD.
    Ichinose M; Fukushima Y; Inoue Y; Hataji O; Ferguson GT; Rabe KF; Hayashi N; Okada H; Takikawa M; Bourne E; Ballal S; DeAngelis K; Aurivillius M; Reisner C; Dorinsky P
    Int J Chron Obstruct Pulmon Dis; 2019; 14():2993-3002. PubMed ID: 31920296
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and Safety of Budesonide/Glycopyrronium/Formoterol Fumarate versus Other Triple Combinations in COPD: A Systematic Literature Review and Network Meta-analysis.
    Bourdin A; Molinari N; Ferguson GT; Singh B; Siddiqui MK; Holmgren U; Ouwens M; Jenkins M; De Nigris E
    Adv Ther; 2021 Jun; 38(6):3089-3112. PubMed ID: 33929661
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Triple therapy in COPD: new evidence with the extrafine fixed combination of beclomethasone dipropionate, formoterol fumarate, and glycopyrronium bromide.
    Singh D; Corradi M; Spinola M; Papi A; Usmani OS; Scuri M; Petruzzelli S; Vestbo J
    Int J Chron Obstruct Pulmon Dis; 2017; 12():2917-2928. PubMed ID: 29062229
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Once-Daily Single-Inhaler Triple versus Dual Therapy in Patients with COPD.
    Lipson DA; Barnhart F; Brealey N; Brooks J; Criner GJ; Day NC; Dransfield MT; Halpin DMG; Han MK; Jones CE; Kilbride S; Lange P; Lomas DA; Martinez FJ; Singh D; Tabberer M; Wise RA; Pascoe SJ;
    N Engl J Med; 2018 May; 378(18):1671-1680. PubMed ID: 29668352
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of budesonide/glycopyrronium/formoterol metered dose inhaler in patients with COPD: post-hoc analysis from the KRONOS study excluding patients with airway reversibility and high eosinophil counts.
    Muro S; Sugiura H; Darken P; Dorinsky P
    Respir Res; 2021 Jun; 22(1):187. PubMed ID: 34182998
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative Effectiveness and Safety of Different Types of Inhaled Long-Acting β
    Wang MT; Lai JH; Huang YL; Liou JT; Cheng SH; Lin CW; Pan HY; Hsu YJ; Tsai CL
    Chest; 2021 Oct; 160(4):1255-1270. PubMed ID: 34023320
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomized, seven-day study to assess the efficacy and safety of a glycopyrrolate/formoterol fumarate fixed-dose combination metered dose inhaler using novel Co-Suspension™ Delivery Technology in patients with moderate-to-very severe chronic obstructive pulmonary disease.
    Reisner C; Fabbri LM; Kerwin EM; Fogarty C; Spangenthal S; Rabe KF; Ferguson GT; Martinez FJ; Donohue JF; Darken P; St Rose E; Orevillo C; Strom S; Fischer T; Golden M; Dwivedi S
    Respir Res; 2017 Jan; 18(1):8. PubMed ID: 28061907
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and Safety of Budesonide/Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler Formulated Using Co-Suspension Delivery Technology in Japanese Patients with COPD: A Subgroup Analysis of the KRONOS Study.
    Ichinose M; Fukushima Y; Inoue Y; Hataji O; Ferguson GT; Rabe KF; Hayashi N; Okada H; Takikawa M; Bourne E; Ballal S; DeAngelis K; Aurivillius M; Dorinsky P; Reisner C
    Int J Chron Obstruct Pulmon Dis; 2019; 14():2979-2991. PubMed ID: 31920295
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler Improves Lung Function versus Monotherapies in GOLD Category A Patients with COPD: Pooled Data from the Phase III PINNACLE Studies.
    Martinez FJ; Rabe KF; Lipworth BJ; Arora S; Jenkins M; Martin UJ; Reisner C
    Int J Chron Obstruct Pulmon Dis; 2020; 15():99-106. PubMed ID: 32021148
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Single inhaler triple therapy versus inhaled corticosteroid plus long-acting β2-agonist therapy for chronic obstructive pulmonary disease (TRILOGY): a double-blind, parallel group, randomised controlled trial.
    Singh D; Papi A; Corradi M; Pavlišová I; Montagna I; Francisco C; Cohuet G; Vezzoli S; Scuri M; Vestbo J
    Lancet; 2016 Sep; 388(10048):963-73. PubMed ID: 27598678
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 45.